ClinicalTrials.gg
CompletedNCT02782013PROGRESSUpdated Oct 17, 2022

Study of Progression of Community Acquired Pneumonia in the Hospital

An observational study in Pneumonia, Sepsis and Shock, Septic, sponsored by Pneumonia Research Network on Genetic Resistance and Susceptibility for the Evolution of Severe Seps. Completed at 64 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-10-17.

Primary conditionCommunity-Acquired PneumoniaRegistry: PneumoniaReclassifiedWhy we changed it
Registry
Pneumonia — the first condition term the registry derived for this study.
ClinicalTrials.gg
Community-Acquired Pneumonia
Why
  1. The study's title name Community-Acquired Pneumonia, a narrower term within Pneumonia.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Pneumonia Research Network on Genetic Resistance and Susceptibility for the Evolution of Severe Seps · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
2,309
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 23 studies in Community-Acquired Pneumonia with a site in Germany — 5 open to participants now, 5 under way, 3 of them phase 3. Community-Acquired Pneumonia · Germany.

Started
2009
the only one that year
Observational
7 of 23
2 open now
Registered
12th of 23
by date

Among the 23 studies in Community-Acquired Pneumonia with a site in Germany, this one is the only one that started in 2009, is one of 7 observational ones, and was the 12th registered.

Community-Acquired Pneumonia

325 studies on the registry are indexed under Community-Acquired Pneumonia; 77 are open to participants now.

Browse Community-Acquired Pneumonia studies →

Open to participants now

5 of the 23 studies in Community-Acquired Pneumonia with a site in Germany are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 41 Community-Acquired Pneumonia studies recruiting now, 29 (71%) set no upper age limit and 9 (22%) stop at 75 or younger; 13 take children under 18; 5 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Community-Acquired Pneumonia with a site in Germany, or all of them as a file.
02

Study summary

Pneumonia is a common infectious disease of the lung, often requiring treatment in the hospital. Clinical scoring systems are available, identifying patients not requiring hospitalization. However, the course of disease of patients in the hospital remains hard to predict. While most patients will recover quickly, some will, despite appropriate treatment, develop a severe course leading to sepsis and systemic responses resulting in organ dysfunction. The PROGRESS study aims to identify clinical, genetic, and other molecular markers and combinations thereof predicting a severe course of pneumonia in the hospital. Such predictors will, for instance, support decisions on earlier transfer of patients to intensive care and thus improving outcome.

Read the detailed description

Pneumonia is a common infectious disease of the lung, often requiring treatment in the hospital. Clinical scoring systems are available, identifying patients not requiring hospitalization. However, the course of disease of patients in the hospital remains hard to predict. While most patients will recover quickly, some will, despite appropriate treatment, develop a severe course leading to sepsis and systemic responses resulting in organ dysfunction. The PROGRESS study aims to identify clinical, genetic and other molecular markers and combinations thereof predicting a severe course of pneumonia in the hospital. Such predictors will, for instance, support decisions on earlier transfer of patients to intensive care and thus improving outcome.

The PROGRESS study was initially approved by the ethics board of the University Hospital Jena, Friedrich-Schiller-University Jena, Germany (2403-10/08, November 6th, 2008) and subsequently by the ethics committees of all recruiting study centers.

In this observational, longitudinal case-cohort study, patients are enrolled within 48 hours of hospitalization and patient's progress is followed in much detail for up to six days thereafter. Further data are collected until discharge from the hospital. Patients are followed up on at days 28, 180, and 360 after enrollment.

Baseline assessment comprises sociodemographic, anamnestic, family history, and live style information. Upon enrollment, Pneumonia Severity Index (PSI) and CURB-65 are determined. For the day of enrollment and up to six subsequent study days routine laboratory and clinical observations and information on therapy are documented as well as data for determining the Sequential Organ Failure Assessment (SOFA) score, Systemic Inflammatory Response Syndrome (SIRS) status, and organ dysfunction. Starting with enrollment, up to six consecutive sets of biomaterials are collected comprising serum, plasma, and materials for extraction of RNA. Blood for extraction of DNA is collected once.

Follow up comprises vital status, housing situation, recurrence of pneumonia, and a quality of life questionnaire.

Analysis of cross sectional and time series data will identify clinical, genetic, and other molecular markers predicting a severe course of pneumonia in the hospital. Analysis of multilevel 'omics data in conjunction with clinical data will provide new insights into pathomechanistic details of pneumonia progression.

03

Conditions studied

  • Pneumonia
  • Sepsis
  • Shock, Septic

Keywords

  • community acquired pneumonia
  • CAP
  • disease progression
04

In context

Community-Acquired Pneumonia Reclassified

325 studies on the registry are indexed under Community-Acquired Pneumonia; 77 are open to participants now.

This study's enrollment of 2,309 is above the median of 650 across 111 observational studies indexed under Community-Acquired Pneumonia.

Browse Community-Acquired Pneumonia studies →

Lead sponsor

Pneumonia Research Network on Genetic Resistance and Susceptibility for the Evolution of Severe Seps is the lead sponsor of 2 studies on the registry; 1 is open to participants now.

Compared within Community-Acquired Pneumonia, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Pneumonia. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adult patients hospitalized for treatment of community acquired pneumonia. Patients can be enrolled in general care, intensive care, and in emergency departments.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Hospitalization with community acquired pneumonia (CAP) confirmed by pulmonary infiltrate in chest radiograph
  2. Working diagnosis of CAP by enrolling physician
  3. Adult patient >= 18 years of age
  4. Valid form
  5. At least 2 out of the five following clinical symptoms:

    • Fever
    • Cough
    • Purulent sputum
    • Shortness of breath or need for respiratory support
    • Crackling or rales on auscultation, dullness to percussion, or bronchial breathing

Exclusion criteria

Exclusion Criteria:

  1. Participation in this study at an earlier time
  2. Hospitalization for any reason within 28 days prior to hospitalization for the current episode of CAP
  3. More than 48 hours in the hospital before enrollment
  4. Pregnancy
  5. Breastfeeding
  6. Decision on limitation of therapy before enrollment
  7. Known infection or AIDS
  8. Anti-tumor treatment within the past six months
  9. Post-stenotic pneumonia in conjunction with bronchial carcinoma
  10. Therapy with ≥ 20mg for ≥ 14 days before enrollment
  11. Non-steroidal therapy within the past six months
  12. Cytostatic therapy within the past six months
  13. Radiation therapy within the past six months
  14. Bone marrow transplant received
  15. Respiratory support at home via tracheostoma
  16. Cystic fibrosis
  17. Active tuberculosis
  18. Acute lung injury or acute respiratory distress syndrome for extrapulmonary reasons
  19. Massive aspiration
  20. Sepsis with extrapulmonary focus
  21. Acute pulmonary embolism
  22. Congestive heart failure (NYHA) IV stadium
  23. Liver insufficiency C stadium
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

06

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
2,309 participants (actual)
Patient registry
No
Biospecimen retention
Samples with dna
07

What researchers measure

Primary outcomes

  1. Worst measure of disease severity

    Disease severity is operationalized by the Sequential Organ Failure Assessment (SOFA-score).

    Time frame: Between enrollment and day six

Secondary outcomes

  1. All cause mortality

    Time frame: up to one year after enrolment

  2. disease-specific mortality

    Time frame: up to one year after enrolment

  3. duration of hospitalization

    Time frame: up to one year after enrolment

  4. duration of intensive care treatment

    Time frame: up to one year after enrolment

  5. duration of ventilator assisted breathing

    Time frame: up to one year after enrolment

08

Study locations

64 sites
  • LKH-Univ. Klinikum Graz, UKIM Pulmologie
    Graz, 8036, Austria
  • Allgemeines Krankenhaus der Stadt Linz, Abteilung Lungenheilkunde
    Linz, 4021, Austria
  • Universitätsklinikum Aachen, Med. Klinik I (Pneumologie)
    Aachen, 52057, Germany
  • Evangel. Krankenhausverein, Luisenhospital, Lungenzentrum
    Aachen, 52064, Germany
  • Krankenhaus Angermünde, Klinik f. Innere Medizin / Pneumologie
    Angermünde, 16278, Germany
  • Krankenhaus Bad Arolsen GmbH, Innere Medizin (Herz-, Kreislauf- u. Lungendiagnostik)
    Bad Arolsen, 34454, Germany
  • Evangelisches Krankenhaus Bad Dürkheim, Innere Medizin
    Bad Dürkheim, 67098, Germany
  • Hochtaunus-Kliniken, Medizinische Klinik III
    Bad Homburg, 61348, Germany
  • Lungenklinik Ballenstedt/Harz gGmbH, Ev. Fachkrankenhaus f. Lungenkrankheiten
    Ballenstedt, 06493, Germany
  • Charité - Universitätsmedizin Berlin, Zentrum Anästhesiologie und Intensivmedizin
    Berlin, 12203, Germany
  • Vivantes Netzwerk f. Gesundheit GmbH Vivantes Klinikum Neukölln, Klinik f. Innere Med. - Pneumologie u.Infektiologie - Thoraxzentrum
    Berlin, 12351, Germany
  • HELIOS Klinikum Berlin-Buch, Interdisziplinäres Notfallzentrum mit Rettungsstelle
    Berlin, 13125, Germany
  • Evangelisches Geriatriezentrum Berlin
    Berlin, 13347, Germany
  • Charité - Universitätsmedizin Berlin, Medizinische Klinik m. S. Infektiologie und Pneumologie
    Berlin, 13353, Germany
  • Humboldt-Klinikum Vivantes, Kardiologie und kons. Intensivmedizin
    Berlin, 13509, Germany
  • Vivantes Klinikum Spandau, Kard., Pneum. und kons. Intensivmedizin
    Berlin, 13585, Germany
  • Gemeinschaftskrankenhaus Havelhöhe, Kardio-Pneumologie
    Berlin, 14089, Germany
  • Berufsgenossenschaftl. Universitätsklinikum Bergmannsheil GmbH, Klinik f. Pneumologie, Allergologie u. Schlafmedizin
    Bochum, 44789, Germany
  • Evangelische Kliniken Bonn, Betriebsstätte Johanniter Krankenhaus, Innere Medizin II
    Bonn, 53113, Germany
  • Med. Klinik d. Forschungszentrum Borstel, Fachkrankenhaus f. Lungenerkrankungen, Infektionen u. Allergien
    Borstel, 23845, Germany
  • Städt. Klinikum Dessau, Innere Medizin
    Dessau-Roßlau, 06847, Germany
  • Klinikum Dortmund gGmbH, Medizinische Klinik (Pneumologie / Infektiologie)
    Dortmund, 44145, Germany
  • Knappschaftskrankenhaus Dortmund, Klinik für Pneumologie
    Dortmund, 44309, Germany
  • Universitätsklinikum Carl Gustav Carus, TU Dresden, Medizinische Klinik 1 - Abteilung Pneumologie
    Dresden, 01307, Germany
  • SRH Wald-Klinikum Gera gGmbH, Medizinische Klinik 2
    Gera, 07548, Germany
  • Uniklinikum Greifswald, Zentrum für Innere Medizin B
    Greifswald, 17489, Germany
  • Krankenhaus Martha-Maria Halle-Dölau, Klinik für Innere Medizin I
    Halle (Saale), 06120, Germany
  • Universitätsklinikum Halle (Saale), Klinik für Innere Medizin III (Kardiologie, Pneumologie, Intensivmedizin, Angiologie)
    Halle (Saale), 06120, Germany
  • Universitätsklinikum Hamburg Eppendorf, Onkologisches Zentrum, Pneumologische Studienzentrale
    Hamburg, 20246, Germany
  • ASKLEPIOS Klinik Wandsbek, 1. Medizinische Abteilung
    Hamburg, 22043, Germany
  • Medizinische Hochschule Hannover, Klinik für Pneumologie
    Hannover, 30652, Germany
  • Klinkum Heidenheim, Medizinische Klinik II & Innere Intensiv
    Heidenheim, 89522, Germany
  • Kliniken d. Main-Taunus-Kreises, Klinik f. Pneumologie u. Allg. Innere Medizin
    Hofheim, 65719, Germany
  • Universitätsklinikum des Saarlandes, Innere Medizin V
    Homburg/Saar, 66421, Germany
  • Universitätsklinikum Jena, Klinik für Anästhesiologie und Intensivtherapie
    Jena, 07747, Germany
  • Universitätsklinikum Jena, Zentrum für Infektionsmedizin und Krankenhaushygiene, Studienabteilung
    Jena, 07747, Germany
  • St.Vincentius-Kliniken gAG, Med. Klinik IV / Pneumologie
    Karlsruhe, 76137, Germany
  • Universitätsklinikum Schleswig-Holstein - Campus Kiel, Medizin 1
    Kiel, 24105, Germany
  • Evangelisches Krankenhaus Kalk gGmbH, Innere Medizin / Pneumologie
    Köln, 51103, Germany
  • Universität Leipzig, Innere Medizin, Neurologie und Dermatologie, Pneumologie / Studiensekretariat
    Leipzig, 04103, Germany
  • Klinikum St. Georg gGmbH, Klinik für Infektions-/Tropenmedizin und Nephrologie
    Leipzig, 04129, Germany
  • Franziskus Krankenhaus Linz, Innere Abteilung
    Linz, 53545, Germany
  • Universitätsklinikum Schleswig-Holstein - Campus Lübeck, Med. Klinik III (Pneumologie)
    Lübeck, 23538, Germany
  • St. Vincenz und Elisabeth Hospital Mainz, Innere Medizin
    Mainz, 55130, Germany
  • Universitätsmedizin Mannheim, Studienkoordinierungszentrum, 1. Medizinische Klinik
    Mannheim, 68167, Germany
  • Städtisches Klinikum München GmbH - Klinikum Harlaching, Klinik für Gastroent., Pneum., intern. Akut- u. Intensivmedizin
    München, 81545, Germany
  • Krankenhaus München-Neuperlach, Klinik für Kardiologie, Pneumologie und Internistische Intensivmedizin
    München, 81737, Germany
  • Universitätsklinikum Münster, Kardiologie 1
    Münster, 48149, Germany
  • Dietrich-Bonhoeffer-Klinikum, Klinik f. Innere Medizin 2 (Abt. Pulmologie)
    Neubrandenburg, 17039, Germany
  • Ev. Fachkrankenhaus für Atemwegserkrankungen
    Neustadt, 99762, Germany
  • Pius-Hospital Oldenburg, Klinik f. Innere Med., Abt. f. Pneumologie
    Oldenburg, 26121, Germany
  • Brüderkrankenhaus St. Josef, Medizinische Klinik
    Paderborn, 33098, Germany
  • Christliches Krankenhaus Quakenbrück e. V., Med. Klinik (Abtl. Pneumologie, Allergologie, Schlafmedizin)
    Quakenbrück, 49610, Germany
  • Universitätsklinikum Regensburg, Klinik Innere Medizin I, Intensivmedizin, Endokrinologie
    Regensburg, 93053, Germany
  • Mathias-Spital Rheine, Klinik für Pneumologie und Thoraxonkologie
    Rheine, 48431, Germany
  • Diakoniekrankenhaus Rotenburg(Wümme)gGmbH, Zentrum für Pneumologie
    Rotenburg/Wümme, 27356, Germany
  • Altmark-Klinikum gGmbH, Krankenhaus Salzwedel
    Salzwedel, 29410, Germany
  • HELIOS Kliniken Schwerin GmbH, Klinik für Internistische und Neurologische Intensivmedizin/Stroke Unit
    Schwerin, 19049, Germany
  • Krankenhaus Bethanien gGmbH Solingen, Abt. Pneumologie
    Solingen, 42699, Germany
  • Kreisklinik Trostberg, Innere Abteilung
    Trostberg, 83308, Germany
  • Universitätsklinikum Ulm, Klinik für Innere Medizin II, Sudienzentrale Innere II, Sektion Pneumologie
    Ulm, 89081, Germany
  • HELIOS Klinikum Wuppertal, Klinik für Intensivmedizin
    Wuppertal, 42283, Germany
  • HELIOS Klinikum Wuppertal, Pneumologie, Bergisches Lungenzentrum
    Wuppertal, 42283, Germany
  • Missionsärztliche Klinik GmbH Würzburg, Innere Medizin (Pneumologie)
    Würzburg, 97074, Germany
09

References and documents

Publications

  • Rosolowski M, Oberle V, Ahnert P, Creutz P, Witzenrath M, Kiehntopf M, Loeffler M, Suttorp N, Scholz M. Dynamics of cytokines, immune cell counts and disease severity in patients with community-acquired pneumonia - Unravelling potential causal relationships. Cytokine. 2020 Dec;136:155263. doi: 10.1016/j.cyto.2020.155263. Epub 2020 Sep 4. PubMed 32896803 ↗
  • Ahnert P, Creutz P, Horn K, Schwarzenberger F, Kiehntopf M, Hossain H, Bauer M, Brunkhorst FM, Reinhart K, Volker U, Chakraborty T, Witzenrath M, Loffler M, Suttorp N, Scholz M; PROGRESS Study Group. Sequential organ failure assessment score is an excellent operationalization of disease severity of adult patients with hospitalized community acquired pneumonia - results from the prospective observational PROGRESS study. Crit Care. 2019 Apr 4;23(1):110. doi: 10.1186/s13054-019-2316-x. PubMed 30947753 ↗
  • Ahnert P, Creutz P, Scholz M, Schutte H, Engel C, Hossain H, Chakraborty T, Bauer M, Kiehntopf M, Volker U, Hammerschmidt S, Loeffler M, Suttorp N; PROGRESS study group. PROGRESS - prospective observational study on hospitalized community acquired pneumonia. BMC Pulm Med. 2016 Jul 28;16(1):108. doi: 10.1186/s12890-016-0255-8. PubMed 27535544 ↗

Individual participant data

Plan to share: Yes — Anonymized individual participant data will be made available after conclusion of the study. Participants can apply for clinical and molecular study data by sending structured project proposals to the PROGRESS board. The PROGRESS board will evaluate proposals for scientific quality, adherence to the limits set by patient's informed consent statements and by intellectual property regulations of the funding agency. Proposals shall not be denied without concrete reason.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2009 to primary completion in Jun 2022, 153 months.

Of 38 observational studies under Community-Acquired Pneumonia, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 57. This study's 153 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
May 19, 2016
First posted
May 25, 2016
StartActual
Aug 25, 2009
Primary completionActual
Jun 1, 2022
CompletionActual
Jun 1, 2022
Last update
Oct 17, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 17, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02782013
Lead sponsor
Pneumonia Research Network on Genetic Resistance and Susceptibility for the Evolution of Severe Seps
Collaborators
University of Leipzig, Jena University Hospital, University of Giessen, University Medicine Greifswald, Charite University, Berlin, Germany, German Federal Ministry of Education and Research
Responsible party
Sponsor
First posted
May 25, 2016
Start date
Aug 25, 2009
Primary completion
Jun 1, 2022
Completion
Jun 1, 2022
Last update
Oct 17, 2022

Study contacts

Norbert Suttorp, MD
principal investigator · Charite University, Berlin, Germany

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion